Lanean...

Access to orphan drugs despite poor quality of clinical evidence

AIM: We analysed the Belgian reimbursement decisions of orphan drugs as compared with those of innovative drugs for more common but equally severe diseases, with special emphasis on the quality of clinical evidence. METHODS: Using the National Health Insurance Agency administrative database, we eval...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Dupont, Alain G, Van Wilder, Philippe B
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Blackwell Science Inc 2011
Gaiak:
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC3080635/
https://ncbi.nlm.nih.gov/pubmed/21395641
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1365-2125.2010.03877.x
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!